HPV Vaccination Recommendation for a 19-Year-Old Female
A 19-year-old female should receive the 9-valent HPV vaccine (Gardasil 9) using a 3-dose schedule at 0,2, and 6 months, regardless of prior sexual activity or HPV exposure status.
Rationale for Vaccination at Age 19
The evidence strongly supports catch-up vaccination for females aged 13-26 years who have not been previously vaccinated 1. At 19 years old, this patient falls squarely within the recommended catch-up vaccination age range. While ideally HPV vaccination should occur before sexual debut (typically recommended at ages 11-12), the majority of 19-year-old females will still derive substantial benefit from vaccination 1.
Even if sexually active, most young women have not been infected with all four original vaccine HPV types, and the 9-valent vaccine protects against nine types total 1. Type-specific prevalence studies show that only a small percentage of sexually active females have been infected with all vaccine HPV types 1. Therefore, vaccination provides protection against the HPV types to which she has not yet been exposed.
Dosing Schedule
For individuals 15 years and older, a 3-dose schedule is required 2:
- Dose 1: Initial dose
- Dose 2: 2 months after the first dose
- Dose 3: 6 months after the first dose
The 2-dose schedule is only appropriate for individuals who initiate vaccination before their 15th birthday 3, 2. Since this patient is 19 years old, she requires the full 3-dose series.
Minimum Acceptable Intervals
If scheduling flexibility is needed 1:
- Minimum interval between doses 1 and 2: 4 weeks
- Minimum interval between doses 2 and 3: 12 weeks
- Minimum interval between doses 1 and 3: 24 weeks
If doses are given at shorter-than-recommended intervals, they should be repeated.
Vaccine Selection
The 9-valent HPV vaccine (Gardasil 9) is the only HPV vaccine currently available in the United States as of January 2017 3. It protects against:
- HPV types 6,11,16,18 (original quadrivalent coverage)
- HPV types 31,33,45,52,58 (additional high-risk types)
This provides protection against approximately 70% of cervical cancers (types 16 and 18) plus an additional 14% of cervical cancers from the five additional high-risk types 3. It also prevents approximately 90% of genital warts (types 6 and 11) 1, 3.
Important Clinical Considerations
No Pre-Vaccination Testing Required
Do not perform Pap testing, HPV DNA testing, or HPV antibody testing before vaccination 1. These tests are not needed and should not influence the decision to vaccinate. The presence of abnormal Pap results, genital warts, or positive HPV tests does not contraindicate vaccination 4, 5.
Continued Cervical Cancer Screening
Vaccination does not eliminate the need for routine cervical cancer screening 4, 2. The vaccine does not protect against all oncogenic HPV types, and vaccinated women should continue age-appropriate screening per current guidelines.
Sexual Activity Status
The patient's sexual history should not determine whether to vaccinate. While vaccine effectiveness is highest in those not yet exposed to HPV, sexually active females should still be vaccinated 1. Most will benefit from protection against HPV types to which they have not been exposed.
Administration Details
- Route: Intramuscular injection, preferably in the deltoid muscle 1
- Observe for 15 minutes post-vaccination due to syncope risk in adolescents and young adults 4, 2
- Can be administered concurrently with other vaccines 4, 2
Contraindications and Precautions
Absolute Contraindications 4, 2:
- History of immediate hypersensitivity to yeast
- Severe allergic reaction to any vaccine component (aluminum hydroxyphosphate sulfate, polysorbate 80)
- Previous severe allergic reaction to any HPV vaccine dose
Precautions:
- Defer vaccination if moderate or severe acute illness 4
- Pregnancy: Vaccination is not recommended during pregnancy, though not contraindicated in recent guidance 6. If pregnancy occurs during the series, defer remaining doses until after delivery 4, 2
- Immunocompromised status: Can still receive vaccine (not a live vaccine), though may require 3-dose schedule regardless of age 6
Expected Outcomes
Vaccination at age 19 will significantly reduce this patient's lifetime risk of:
- Cervical cancer and precancerous lesions
- Vulvar and vaginal cancers
- Anal cancer
- Genital warts
The vaccine has demonstrated high efficacy in preventing persistent infection and precancerous lesions in women aged 16-26 years in clinical trials 4, 1.